SuperworthProfusa PFSA
- Market cap
- $508.2K
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- not a meaningful number
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/a | n/a | n/a | n/a | $75K | $0 | n/a | n/a | n/a | n/a | n/a | n/a | |
| R&D | n/a | n/a | n/a | n/a | $411K | $259K | $434K | $393K | $722K+76% | $1.3M+385% | $1.1M+164% | $823K+109% |
| SG&A | n/a | n/a | n/a | n/a | $767K | $823K | $990K | $610K | $21M+2636% | $2.3M+181% | $2.9M+189% | $1.7M+182% |
| −$290.1K−28% | −$460.2K+13% | −$470.8K+6% | −$253.1K−20% | −$1.1M+280% | −$1.1M+135% | −$1.4M+202% | −$1M+296% | −$21.7M+1868% | −$3.6M+230% | −$4M+181% | −$2.5M+154% | |
| Interest expense | n/a | n/a | n/a | n/a | $1.1M | $1.3M | $1.1M | $1.2M | $169K−84% | $25K−98% | $18K−98% | $21K−98% |
| Pre-tax income | −$341.8K | $262.3K−71% | −$798.8K | −$374.5K | $110.7K | −$7.6M | −$1.1M+38% | −$8.2M+2088% | n/a | n/a | n/a | n/a |
| $25.5K−41% | $26.3K−94% | $21.5K−94% | $23K+5% | $19.5K−24% | $16.5K−37% | $19.4K−10% | $2.4K−90% | n/a | n/a | n/a | n/a | |
| Net income | −$367.3K | $236K−51% | −$820.3K | −$397.5K | −$2.5M+580% | −$7.6M | −$2.7M+231% | −$2.3M+491% | −$22.2M+789% | −$8.6M+13% | −$3.5M+27% | −$8.8M+273% |
| −$450.00 | $375.00−44% | −$1050.00 | −$525.00 | −$9675.00+2050% | −$10950.00 | −$10509.00+901% | −$9100.78+1634% | −$5250.00−46% | n/a | −$205.00−98% | −$151.80−98% | |
| 693+0% | 693+0% | 693+0% | 693+0% | 258−63% | 741+7% | 258−63% | 258−63% | 4.2K+1537% | n/a | 16.9K+6432% | 57.7K+22255% |
EPS, diluted: 7 periods, Q4 FY21 to Q4 FY24: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY21: share-days: the 9-month average less the 6-month, weighted by days. Q4 FY22 and Q4 FY23: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY24: share-days: the 12-month average over 366 days less the 9-month over 274, the two on one basis (x201).
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Profusa's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| PFSAProfusa | $508.2K | n/m | n/a | n/m | n/m | n/m | |
| GCTKGlucotrack | $284.4K | n/m | n/a | n/m | n/m | n/m | |
| VJETFlyte Aviation | $1M | n/m | n/a | 0.5× | +219% | n/m | |
| BBLGBone Biologics | $1.1M | n/m | n/a | n/m | n/m | n/m | |
| IVFINVO Fertility | $1.4M | n/m | n/a | 0.2× | +14% | −70.2% | |
| TNONTenon Medical | $1.5M | n/m | n/a | 0.3× | +80% | n/m | |
| XAIRBeyond Air | $2M | n/m | n/a | 0.3× | +61% | n/m | |
| ADGMAdagio Medical | $2.3M | n/m | n/a | n/a | n/m | n/a | |
| AMIXAutonomix Medical | $2.3M | n/m | n/a | n/m | n/m | n/m | |
| NXGLNexgel | $2.5M | n/m | n/a | n/m | n/m | n/m | |
| BJDXBluejay Diagnostics | $2.6M | n/m | n/a | n/m | n/m | n/m | |
| Peer median | $1.7M | n/a | n/a | 0.3× | +70% | −70.2% |
More on Profusa
Each number over time
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .